- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 - - Initiation of Phase 1 trial of second precision program PRA052 - - Strong cash position provides runway into mid-2024 - SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc.

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one of the strongest genetic

SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment

- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022  - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging study - - Unveiled Prometheus’ second precision candidate, PRA052, a first-in-class monoclonal

- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - - PRA052 is a novel, first-in-class monoclonal antibody addressing a target with one of the strongest genetic

- Global Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies - - Enrollment initiated in Cohort 2 of CDx+ patients to evaluate the company’s companion diagnostic - -  Both APOLLO-CD and ARTEMIS-UC topline results on track for

- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - - Both APOLLO-CD and ARTEMIS-UC topline results expected 4Q 2022 – SAN DIEGO, June 08, 2022 (GLOBE

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - - Announced key appointments in Leadership Team - - Strong cash position of $227 million as of March 31, 2022 -